Rasalect
✅ Parkinson’s symptom relief
✅ Movement improvement
✅ Tremor reduction
✅ Stiffness alleviation
✅ Enhanced motor function
Rasalect contains Rasagiline.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer
Rasalect is an oral rasagiline (1 mg) tablet — a selective monoamine oxidase type B (MAO-B) inhibitor used to treat Parkinson disease. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Unlike selegiline, rasagiline is not metabolised to amphetamine derivatives, so insomnia is much less of a problem. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Important: avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotonin syndrome.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Rasalect?
Rasalect is an oral tablet containing rasagiline 1 mg. rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor originally introduced as Azilect. Rasalect is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.
Rasagiline was developed as a second-generation MAO-B inhibitor specifically to avoid selegiline’s amphetamine metabolites. It has a clean active metabolite (aminoindan) which itself has neuroprotective properties in laboratory models. Rasagiline can be used as monotherapy in early Parkinson disease or as adjunct to levodopa for end-of-dose wearing-off.
How Does Rasalect (rasagiline) Work?
Rasagiline irreversibly inactivates MAO-B in the brain, slowing the breakdown of dopamine. Like selegiline it is selective for MAO-B at therapeutic doses (1 mg/day) but loses selectivity above 1.5–2 mg/day. Its main metabolite, aminoindan, has its own potential neuroprotective activity in preclinical models — the basis for the ADAGIO disease-modification trial, which produced suggestive but not conclusive results.
Comparing the MAO-B Inhibitors
The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:
| Feature | Selegiline | Rasagiline | Safinamide |
|---|---|---|---|
| Typical dose | 5–10 mg/day | 0.5–1 mg/day | 50–100 mg/day |
| Active metabolites | Amphetamine + methamphetamine | Aminoindan (non-amphetamine) | No active stimulant metabolite |
| Glutamate effect | No | No | Yes — sodium-channel/glutamate-release modulation |
| Indication | Monotherapy or adjunct | Monotherapy or adjunct | Adjunct only — for fluctuating PD on levodopa |
| Insomnia risk | Higher (amphetamine metabolites) | Low | Low |
Who Is Rasalect For?
Rasalect is appropriate for adults with Parkinson disease — either as monotherapy in early disease or as adjunct to levodopa in patients with motor fluctuations. Compared with selegiline, rasagiline is preferred when insomnia is a concern. Compared with safinamide, rasagiline is the better monotherapy option (safinamide is licensed only as adjunct).
Dosing and Administration
The standard adult dose is 1 mg once daily, taken in the morning with or without food. There is no need for titration — full effect is reached within 1–2 weeks. Doses above 1 mg/day are generally avoided as MAO-B selectivity is lost. In moderate hepatic impairment reduce to 0.5 mg/day; in severe hepatic impairment avoid.
| Population | Dose |
|---|---|
| Standard adult | 1 mg once daily, morning |
| Mild hepatic impairment | 0.5 mg once daily |
| Moderate-severe hepatic impairment | Avoid |
Common Side Effects
Headache (the most common — usually transient), arthralgia, dyspepsia, depression, postural hypotension, flu-like symptoms. Less common: hallucinations, insomnia (much less than selegiline), weight loss, falls. With levodopa: increased dyskinesia.
Drug and Food Interactions
- Antidepressants — SSRIs, SNRIs, TCAs: avoid. If a serotonergic antidepressant is essential, mirtazapine or bupropion are sometimes used cautiously under specialist supervision.
- Opioids — pethidine, tramadol, methadone: contraindicated. Morphine, codeine, oxycodone are safer alternatives if analgesia is required.
- Sympathomimetics — pseudoephedrine, phenylephrine, ephedrine: risk of hypertensive crisis. Avoid OTC decongestants.
- Other MAO inhibitors — phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue: contraindicated.
- CYP1A2 inducers/inhibitors — rasagiline is metabolised primarily by CYP1A2. Strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) raise rasagiline levels — halve the dose to 0.5 mg/day. Smoking induces CYP1A2 and lowers levels.
- Levodopa — intentional combination: start at the lower MAO-B dose and watch for dyskinesia (a sign that levodopa effect has been amplified). Levodopa dose may need a 10–30% reduction.
Frequently Asked Questions
Can I take Rasalect instead of levodopa?
Yes. Rasagiline 1 mg/day is licensed and effective as monotherapy in early Parkinson disease, with modest but real symptom benefit. As disease progresses, levodopa is almost always added.
How quickly will I feel an effect?
MAO-B inhibitors work gradually. Most patients notice a smoother “on” period and reduced “off” time within 2–4 weeks. The full benefit on motor fluctuations is usually clear by 4–8 weeks.
Will I have to follow a low-tyramine diet?
At normal prescribed doses (selegiline ≤ 10 mg/day, rasagiline 1 mg/day, safinamide ≤ 100 mg/day), no special diet is required. Above those doses, MAO-B selectivity is lost and tyramine restriction becomes important.
Does Rasalect slow down Parkinson disease itself?
A neuroprotective or disease-modifying effect of MAO-B inhibitors has been studied (e.g. the DATATOP and ADAGIO trials with selegiline and rasagiline). Results are suggestive but not definitive. The drugs are prescribed primarily for symptom control, not as guaranteed disease-modifying therapy.
What if I miss a dose?
Take the missed dose as soon as you remember that day. If it is already evening or close to bedtime, skip it — selegiline and rasagiline can both cause insomnia, and a late dose can disrupt sleep. Never double-dose. Resume normal schedule the next day.
Can I drink alcohol with Rasalect?
Moderate alcohol is not strictly forbidden, but heavy drinking and red-wine binges can interact with residual MAO inhibition and increase blood-pressure variability. Many Parkinson patients also have postural hypotension on dopaminergic therapy — alcohol worsens this. Limit to 1 standard drink occasionally.
Can I drive while taking Rasalect?
Most patients tolerate Rasalect without driving impairment. However, dopaminergic therapy as a whole can cause sudden-onset sleep (sleep attacks), particularly when Rasalect is added to a dopamine agonist or levodopa. Until you know how you respond, avoid driving long distances or operating heavy machinery.
Is Rasalect safe in older adults?
Yes — rasagiline is widely used in elderly Parkinson patients. Watch for postural hypotension (rise from sitting slowly), confusion, hallucinations, and impulse-control changes. Lower starting doses may be appropriate.
Can Rasalect be stopped abruptly?
No. Sudden withdrawal of any dopaminergic agent in a Parkinson patient can precipitate a neuroleptic-malignant-like syndrome with rigidity, fever and altered consciousness. If discontinuation is needed, taper over 1–2 weeks under medical supervision.
Will Rasalect cause weight loss or weight gain?
Neither markedly. Some patients on selegiline lose a small amount of weight (the amphetamine-like metabolites can suppress appetite slightly). Rasagiline and safinamide are weight-neutral.
How does MedsBase ship Rasalect?
Worldwide shipping in discreet packaging from a WHO-GMP certified manufacturer. Tablets are shipped in original sealed blister packs. Track your order from your MedsBase account.
Storage
Store at room temperature (15–30°C / 59–86°F), protected from heat, moisture and direct light. Keep in the original container with the lid tightly closed. Keep out of reach of children. Do not use beyond the expiry date printed on the packaging.
Medical Disclaimer
This information is provided for educational purposes only and is not a substitute for the advice of a qualified clinician. Parkinson disease and parkinsonian syndromes require individualised neurology care. Discuss all medications, supplements and pre-existing conditions with your doctor before starting, changing or stopping treatment. Do not abruptly discontinue dopaminergic therapy — sudden withdrawal can precipitate a neuroleptic malignant-like syndrome.
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in Parkinson's Disease Treatment
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 1 mg |
|---|---|
| Quantity | 10 Tablet/s, 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Rasalect
Ερωτήσεις & Απαντήσεις
Rasalect
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές